Niagen Bioscience (formerly ChromaDex)
Bioscience company supplying nicotinamide riboside, a patented NAD precursor ingredient.
- MOQ
- Not publicly disclosed
- LEAD TIME
- Not publicly disclosed
Overview
Niagen Bioscience (NASDAQ: NAGE), formerly ChromaDex, is a publicly traded bioscience company that pioneered the commercialization of nicotinamide riboside (NR), an NAD+ precursor. Their flagship ingredient Niagen (nicotinamide riboside chloride) is patented, has received FDA NDI notification, and has been the subject of published human clinical studies. The company holds licensed patents from Cornell University, Dartmouth College, and Washington University in St. Louis. Niagen Bioscience also sells Tru Niagen directly to consumers. The company was renamed from ChromaDex to Niagen Bioscience in March 2025. Based in Los Angeles, California.
Certifications
No certifications on record.
INGREDIENT REGULATORY STATUS
- NDI-Notified IngredientNew dietary ingredient notification filed with FDA: Nicotinamide riboside chloride (Niagen) (NDIN 882 (2015) and NDIN 1062 (2017), filed as ChromaDex) · source
Capabilities
- PRODUCT TYPES
- Nicotinamide Riboside (Niagen) · NAD+ Precursor Ingredients
- CAPABILITIES
- Branded or patented ingredients · Clinical research or study support · Amino acids or specialty nutrients
Sources
- Niagen Bioscience (ChromaDex) - Official Website(2026-03-26)
- Niagen Bioscience - Wikipedia(2026-03-26)
- NutraIngredients - ChromaDex NDI for Niagen(2026-03-26)
What we couldn't verify
We did not visit this company on site. See the limits that apply to every listing.
- Single-ingredient focus (nicotinamide riboside); not a broad ingredient supplier
- Company renamed from ChromaDex to Niagen Bioscience in March 2025; some confusion in market
- Also operates a competing consumer brand (Tru Niagen)
Dietary supplement manufacturers must comply with 21 CFR Part 111 (cGMP). What Part 111 requires
Disclosures
- Niagen Bioscience is publicly traded (NASDAQ: NAGE)
- Company was formerly known as ChromaDex; renamed March 2025
The connection map between Niagen Bioscience (formerly ChromaDex) and other vendors, capabilities, and certifications is in the manufacturer atlas.
Enforcement screening: included in Inventory Ready's most recent completed pass against FDA's published recall datasets (2026-07-09). Method and limits →
Interested in Niagen Bioscience (formerly ChromaDex)?
Tell us about your project and we'll help you determine if this ingredient supplier is a good fit.